Logo image of SGHT

SIGHT SCIENCES INC (SGHT) Stock Price, Quote, News and Overview

NASDAQ:SGHT - Nasdaq - US82657M1053 - Common Stock - Currency: USD

2.8  +0.07 (+2.56%)

After market: 2.8 0 (0%)

SGHT Quote, Performance and Key Statistics

SIGHT SCIENCES INC

NASDAQ:SGHT (2/4/2025, 8:07:23 PM)

After market: 2.8 0 (0%)

2.8

+0.07 (+2.56%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High8.45
52 Week Low2.68
Market Cap142.10M
Shares50.75M
Float40.22M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-15 2021-07-15


SGHT short term performance overview.The bars show the price performance of SGHT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

SGHT long term performance overview.The bars show the price performance of SGHT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SGHT is 2.8 USD. In the past month the price decreased by -19.77%. In the past year, price decreased by -38.33%.

SIGHT SCIENCES INC / SGHT Daily stock chart

SGHT Latest News, Press Releases and Analysis

News Image
3 months ago - Sight Sciences, Inc.

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (

News Image
4 months ago - Sight Sciences, Inc.

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...

News Image
4 months ago - Sight Sciences, Inc.

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients...

SGHT Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.64 223.92B
ISRG INTUITIVE SURGICAL INC 79.08 206.46B
BSX BOSTON SCIENTIFIC CORP 43.87 152.60B
SYK STRYKER CORP 32.19 149.59B
MDT MEDTRONIC PLC 17.33 116.65B
BDX BECTON DICKINSON AND CO 18.42 70.30B
EW EDWARDS LIFESCIENCES CORP 26.72 42.07B
GEHC GE HEALTHCARE TECHNOLOGY 20.6 39.72B
IDXX IDEXX LABORATORIES INC 41.34 38.08B
RMD RESMED INC 27.2 35.30B
DXCM DEXCOM INC 51.45 34.16B
PHG KONINKLIJKE PHILIPS NVR- NY 20.39 25.29B

About SGHT

Company Profile

SGHT logo image Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company is headquartered in Menlo Park, California and currently employs 214 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.

Company Info

SIGHT SCIENCES INC

4040 Campbell Ave,, Suite 100

Menlo Park CALIFORNIA US

CEO: Paul Badawi

Employees: 214

Company Website: https://www.sightsciences.com/

Investor Relations: https://investors.sightsciences.com/

Phone: 14158890550

SGHT FAQ

What is the stock price of SGHT?

The current stock price of SGHT is 2.8 USD.


What is the symbol for SIGHT SCIENCES INC stock?

The exchange symbol of SIGHT SCIENCES INC is SGHT and it is listed on the Nasdaq exchange.


On which exchange is SGHT stock listed?

SGHT stock is listed on the Nasdaq exchange.


Is SGHT a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SGHT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SGHT.


Does SGHT stock pay dividends?

SGHT does not pay a dividend.


What is the Price/Earnings (PE) ratio of SGHT?

SGHT does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).


What is the Short Interest ratio of SGHT stock?

The outstanding short interest for SGHT is 2.66% of its float.


SGHT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SGHT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SGHT. The financial health of SGHT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SGHT Financial Highlights

Over the last trailing twelve months SGHT reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS decreased by 19.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -35.06%
ROE -53.03%
Debt/Equity 0.36
Chartmill High Growth Momentum
EPS Q2Q%18.52%
Sales Q2Q%0.74%
EPS 1Y (TTM)19.69%
Revenue 1Y (TTM)-3.98%

SGHT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to SGHT. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 13.13% and a revenue growth -0.37% for SGHT


Ownership
Inst Owners50.96%
Ins Owners19.42%
Short Float %2.66%
Short Ratio4.79
Analysts
Analysts74.29
Price Target4.61 (64.64%)
EPS Next Y13.13%
Revenue Next Year-0.37%